Mario Occhipinti

2.2k total citations
34 papers, 237 citations indexed

About

Mario Occhipinti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Mario Occhipinti has authored 34 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Mario Occhipinti's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mario Occhipinti is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mario Occhipinti collaborates with scholars based in Italy, United States and Germany. Mario Occhipinti's co-authors include Paolo Marchetti, Concetta Elisa Onesti, Andrea Botticelli, Federica Mazzuca, Bruna Cerbelli, Lidia Strigari, Francesca Romana Di Pietro, Marianna Nuti, Rosa Falcone and Michela Roberto and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mario Occhipinti

31 papers receiving 234 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Occhipinti Italy 9 163 88 51 42 23 34 237
Sara Delfanti Italy 10 116 0.7× 95 1.1× 43 0.8× 58 1.4× 17 0.7× 32 254
Sanjeev Deva New Zealand 9 179 1.1× 60 0.7× 64 1.3× 64 1.5× 19 0.8× 37 249
Camille L. Gérard Switzerland 10 196 1.2× 85 1.0× 80 1.6× 97 2.3× 15 0.7× 33 300
Joan Tymon‐Rosario United States 8 103 0.6× 45 0.5× 39 0.8× 67 1.6× 24 1.0× 34 294
Annelieke E.C.A.B. Willemsen Netherlands 10 145 0.9× 102 1.2× 40 0.8× 89 2.1× 15 0.7× 25 298
Blessie Elizabeth Nelson United States 10 126 0.8× 47 0.5× 62 1.2× 63 1.5× 18 0.8× 33 249
Sreekanth Reddy United States 6 178 1.1× 96 1.1× 16 0.3× 72 1.7× 24 1.0× 11 289
Aya El Helali Hong Kong 9 108 0.7× 59 0.7× 39 0.8× 94 2.2× 26 1.1× 34 288
Ivan Jelas Germany 8 134 0.8× 33 0.4× 34 0.7× 43 1.0× 44 1.9× 22 200
Alexandre Wicky Switzerland 6 94 0.6× 43 0.5× 42 0.8× 37 0.9× 11 0.5× 16 164

Countries citing papers authored by Mario Occhipinti

Since Specialization
Citations

This map shows the geographic impact of Mario Occhipinti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Occhipinti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Occhipinti more than expected).

Fields of papers citing papers by Mario Occhipinti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Occhipinti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Occhipinti. The network helps show where Mario Occhipinti may publish in the future.

Co-authorship network of co-authors of Mario Occhipinti

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Occhipinti. A scholar is included among the top collaborators of Mario Occhipinti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Occhipinti. Mario Occhipinti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Proto, Claudia, Giuseppe Lo Russo, Arsela Prelaj, et al.. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 9(9). e2400790–e2400790. 1 indexed citations
2.
Occhipinti, Mario, et al.. (2025). Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. npj Precision Oncology. 9(1). 219–219.
3.
Stanzi, Alessia, et al.. (2025). Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications. Critical Reviews in Oncology/Hematology. 215. 104864–104864.
4.
Occhipinti, Mario, Marta Brambilla, Raimondo Di Liello, et al.. (2024). Unleashing precision: A review of targeted approaches in pleural mesothelioma. Critical Reviews in Oncology/Hematology. 203. 104481–104481. 6 indexed citations
5.
Lorenzini, Daniele, A. Bassetti, Elena Tamborini, et al.. (2024). Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. Clinical Lung Cancer. 26(1). e11–e17. 1 indexed citations
6.
Moro, Massimo, Chiara Grasselli, Nicolò Panini, et al.. (2024). Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. Journal of Experimental & Clinical Cancer Research. 43(1). 6–6. 11 indexed citations
7.
8.
Lorenzini, Daniele, Mario Occhipinti, Sara Manglaviti, et al.. (2023). 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib. Annals of Oncology. 34. S779–S779. 1 indexed citations
9.
Occhipinti, Mario, Marta Brambilla, Christine Zanella, et al.. (2023). 2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma. Annals of Oncology. 34. S1138–S1138. 1 indexed citations
10.
Zattarin, Emma, Sara Manglaviti, Laura Mazzeo, et al.. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncology. 18(23). 2593–2604. 3 indexed citations
11.
12.
Prelaj, Arsela, Gajanan Bhat, Giuseppina Calareso, et al.. (2022). Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. Frontiers in Oncology. 12. 902967–902967. 6 indexed citations
13.
Occhipinti, Mario, Marta Brambilla, Giulia Galli, et al.. (2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 11(5). 424–424. 8 indexed citations
14.
Prelaj, Arsela, Claudia Proto, Giuseppe Lo Russo, et al.. (2020). 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program. Annals of Oncology. 31. S882–S882. 5 indexed citations
15.
Botticelli, Andrea, Silvia Mezi, Giulia Pomati, et al.. (2020). The 5-Ws of immunotherapy in head and neck cancer. Critical Reviews in Oncology/Hematology. 153. 103041–103041. 13 indexed citations
16.
Occhipinti, Mario, Rosa Falcone, Concetta Elisa Onesti, & Paolo Marchetti. (2018). Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. PubMed. 5(1). 12–12. 15 indexed citations
17.
Occhipinti, Mario, Rosa Falcone, Concetta Elisa Onesti, et al.. (2017). Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. Journal of Thoracic Disease. 9(11). E985–E989. 6 indexed citations
18.
Onesti, Concetta Elisa, Andrea Botticelli, Marco La Torre, et al.. (2016). 5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-Cancer Drugs. 28(3). 322–326. 9 indexed citations
19.
Onesti, Concetta Elisa, Daniela Iacono, Salvatore Di Lauro, et al.. (2016). Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. Translational Lung Cancer Research. 5(6). 712–719. 12 indexed citations
20.
Botticelli, Andrea, Marina Borro, Concetta Elisa Onesti, et al.. (2016). Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. PLoS ONE. 11(9). e0163105–e0163105. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Delfanti Breakdown of academic impact, for papers by Sanjeev Deva Breakdown of academic impact, for papers by Camille L. Gérard Breakdown of academic impact, for papers by Joan Tymon‐Rosario Breakdown of academic impact, for papers by Annelieke E.C.A.B. Willemsen Breakdown of academic impact, for papers by Blessie Elizabeth Nelson Breakdown of academic impact, for papers by Sreekanth Reddy Breakdown of academic impact, for papers by Aya El Helali Breakdown of academic impact, for papers by Ivan Jelas Breakdown of academic impact, for papers by Alexandre Wicky
Rankless by CCL
2026